GINKGO BIOWORKS HOLDINGS INC (DNA) Fundamental Analysis & Valuation

NYSE:DNA • US37611X2099

Current stock price

6.38 USD
-0.07 (-1.09%)
Last:

This DNA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. DNA Profitability Analysis

1.1 Basic Checks

  • In the past year DNA has reported negative net income.
  • In the past year DNA has reported a negative cash flow from operations.
  • DNA had negative earnings in each of the past 5 years.
  • DNA had a negative operating cash flow in each of the past 5 years.
DNA Yearly Net Income VS EBIT VS OCF VS FCFDNA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 -500M -1B -1.5B -2B

1.2 Ratios

  • The Return On Assets of DNA (-27.93%) is worse than 75.44% of its industry peers.
  • With a Return On Equity value of -61.50%, DNA is not doing good in the industry: 73.68% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -27.93%
ROE -61.5%
ROIC N/A
ROA(3y)-40.42%
ROA(5y)-58.5%
ROE(3y)-73.09%
ROE(5y)-92.41%
ROIC(3y)N/A
ROIC(5y)N/A
DNA Yearly ROA, ROE, ROICDNA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 -20 -40 -60 -80 -100

1.3 Margins

  • Looking at the Gross Margin, with a value of 72.39%, DNA belongs to the top of the industry, outperforming 92.98% of the companies in the same industry.
  • DNA's Gross Margin has declined in the last couple of years.
  • The Profit Margin and Operating Margin are not available for DNA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 72.39%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.14%
GM growth 5Y-1.86%
DNA Yearly Profit, Operating, Gross MarginsDNA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025 0 -200 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. DNA Health Analysis

2.1 Basic Checks

  • DNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, DNA has more shares outstanding
  • DNA has less shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, DNA has an improved debt to assets ratio.
DNA Yearly Shares OutstandingDNA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B
DNA Yearly Total Debt VS Total AssetsDNA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B 2.5B

2.2 Solvency

  • Based on the Altman-Z score of -7.68, we must say that DNA is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of DNA (-7.68) is worse than 89.47% of its industry peers.
  • DNA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -7.68
ROIC/WACCN/A
WACC10.8%
DNA Yearly LT Debt VS Equity VS FCFDNA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 500M 1B 1.5B

2.3 Liquidity

  • A Current Ratio of 4.92 indicates that DNA has no problem at all paying its short term obligations.
  • DNA has a Current ratio of 4.92. This is in the better half of the industry: DNA outperforms 77.19% of its industry peers.
  • A Quick Ratio of 4.92 indicates that DNA has no problem at all paying its short term obligations.
  • With an excellent Quick ratio value of 4.92, DNA belongs to the best of the industry, outperforming 85.96% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.92
Quick Ratio 4.92
DNA Yearly Current Assets VS Current LiabilitesDNA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. DNA Growth Analysis

3.1 Past

  • DNA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 36.91%, which is quite impressive.
  • DNA shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -25.06%.
  • Measured over the past years, DNA shows a quite strong growth in Revenue. The Revenue has been growing by 17.28% on average per year.
EPS 1Y (TTM)36.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%29.5%
Revenue 1Y (TTM)-25.06%
Revenue growth 3Y-29.11%
Revenue growth 5Y17.28%
Sales Q2Q%-23.84%

3.2 Future

  • The Earnings Per Share is expected to grow by 15.07% on average over the next years. This is quite good.
  • Based on estimates for the next years, DNA will show a very strong growth in Revenue. The Revenue will grow by 21.73% on average per year.
EPS Next Y33.92%
EPS Next 2Y20.72%
EPS Next 3Y12.68%
EPS Next 5Y15.07%
Revenue Next Year-7.98%
Revenue Next 2Y-4.72%
Revenue Next 3Y19.44%
Revenue Next 5Y21.73%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
DNA Yearly Revenue VS EstimatesDNA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
DNA Yearly EPS VS EstimatesDNA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -10 -20 -30 -40 -50

More info and screens

Find the best growth stocksShow best growing peers

0

4. DNA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for DNA. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DNA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DNA Price Earnings VS Forward Price EarningsDNA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DNA Per share dataDNA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5

4.3 Compensation for Growth

  • A more expensive valuation may be justified as DNA's earnings are expected to grow with 12.68% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.72%
EPS Next 3Y12.68%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. DNA Dividend Analysis

5.1 Amount

  • DNA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

DNA Fundamentals: All Metrics, Ratios and Statistics

GINKGO BIOWORKS HOLDINGS INC

NYSE:DNA (4/13/2026, 12:04:52 PM)

6.38

-0.07 (-1.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-26
Earnings (Next)05-07
Inst Owners65.3%
Inst Owner Change0.03%
Ins Owners3.3%
Ins Owner Change0.13%
Market Cap375.91M
Revenue(TTM)170.16M
Net Income(TTM)-312.76M
Analysts41.82
Price Target10.2 (59.87%)
Short Float %16.8%
Short Ratio6.68
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-5.86%
Min EPS beat(2)-15.78%
Max EPS beat(2)4.05%
EPS beat(4)3
Avg EPS beat(4)6.2%
Min EPS beat(4)-15.78%
Max EPS beat(4)30.48%
EPS beat(8)6
Avg EPS beat(8)11.86%
EPS beat(12)6
Avg EPS beat(12)-2.45%
EPS beat(16)7
Avg EPS beat(16)-105.18%
Revenue beat(2)0
Avg Revenue beat(2)-5.94%
Min Revenue beat(2)-10.85%
Max Revenue beat(2)-1.02%
Revenue beat(4)2
Avg Revenue beat(4)7.45%
Min Revenue beat(4)-10.85%
Max Revenue beat(4)23.63%
Revenue beat(8)4
Avg Revenue beat(8)16.74%
Revenue beat(12)7
Avg Revenue beat(12)12.66%
Revenue beat(16)11
Avg Revenue beat(16)19.55%
PT rev (1m)0%
PT rev (3m)-6.25%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)7.98%
EPS NY rev (3m)17.54%
Revenue NQ rev (1m)0.17%
Revenue NQ rev (3m)-3.22%
Revenue NY rev (1m)-6.48%
Revenue NY rev (3m)-14.22%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.21
P/FCF N/A
P/OCF N/A
P/B 0.74
P/tB 0.83
EV/EBITDA N/A
EPS(TTM)-5.64
EYN/A
EPS(NY)-3.73
Fwd EYN/A
FCF(TTM)-3.03
FCFYN/A
OCF(TTM)-2.9
OCFYN/A
SpS2.89
BVpS8.63
TBVpS7.67
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -27.93%
ROE -61.5%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 72.39%
FCFM N/A
ROA(3y)-40.42%
ROA(5y)-58.5%
ROE(3y)-73.09%
ROE(5y)-92.41%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.14%
GM growth 5Y-1.86%
F-Score3
Asset Turnover0.15
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 12.99%
Cap/Sales 4.5%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.92
Quick Ratio 4.92
Altman-Z -7.68
F-Score3
WACC10.8%
ROIC/WACCN/A
Cap/Depr(3y)56.7%
Cap/Depr(5y)97.46%
Cap/Sales(3y)16.09%
Cap/Sales(5y)15.45%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%29.5%
EPS Next Y33.92%
EPS Next 2Y20.72%
EPS Next 3Y12.68%
EPS Next 5Y15.07%
Revenue 1Y (TTM)-25.06%
Revenue growth 3Y-29.11%
Revenue growth 5Y17.28%
Sales Q2Q%-23.84%
Revenue Next Year-7.98%
Revenue Next 2Y-4.72%
Revenue Next 3Y19.44%
Revenue Next 5Y21.73%
EBIT growth 1Y33.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year65.43%
EBIT Next 3Y28.62%
EBIT Next 5Y16.96%
FCF growth 1Y53.23%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y46.47%
OCF growth 3YN/A
OCF growth 5YN/A

GINKGO BIOWORKS HOLDINGS INC / DNA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of GINKGO BIOWORKS HOLDINGS INC (DNA) stock?

ChartMill assigns a fundamental rating of 3 / 10 to DNA.


What is the valuation status for DNA stock?

ChartMill assigns a valuation rating of 0 / 10 to GINKGO BIOWORKS HOLDINGS INC (DNA). This can be considered as Overvalued.


Can you provide the profitability details for GINKGO BIOWORKS HOLDINGS INC?

GINKGO BIOWORKS HOLDINGS INC (DNA) has a profitability rating of 1 / 10.